N/A Completed N=10 Treatment

Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease

End Stage Renal Disease

Source: ClinicalTrials.gov NCT00677534 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2014

Primary outcomePrimary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale

Summary

The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Monocyte VDR Expression With Vitamin D Therapy	1899	—

Eligibility Criteria

Inclusion Criteria

End-stage renal disease undergoing maintenance hemodialysis at KUMC outpatient hemodialysis unit
Dialysis vintage of at least 6 months duration
Nutritional vitamin D deficiency, defined as 25(OH)D 500)
History of chronic inflammatory disease process, such as inflammatory bowel, rheumatoid arthritis, lupus, etc.
Cinacalcet therapy
Previous allergy to ergocalciferol
History of parathyroidectomy
Current treatment with immunosuppressant medications
Noncompliance with prescribed hemodialysis regimen (i.e. skipping treatments, ending sessions early)
Functional renal transplant within the last five years

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00677534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.